Technology | Ventricular Assist Devices (VAD) | September 27, 2019

Abiomed Receives FDA PMA Approval for Impella 5.5 With SmartAssist

Minimally invasive, forward flow heart pump indicated for short-term use with improved ease of pump insertion

Abiomed Receives FDA PMA Approval for Impella 5.5 With SmartAssist

September 27, 2019 — Abiomed’s newest heart pump, the Impella 5.5 with SmartAssist, has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for safety and efficacy in the therapy of cardiogenic shock for up to 14 days.

Impella 5.5 with SmartAssist is:

  • Minimally invasive, eliminating the need for a sternotomy or coring of the left ventricle;
  • Designed for heart surgeons, implanted via the axillary artery or the anterior aorta;
  • Forward flow, to provide the patient with coronary flow and renal perfusion;
  • Fully unloading, to reduce the heart’s oxygen demand and work; and
  • Equipped with SmartAssist, designed to provide weaning algorithms to optimize survival and native heart recovery.

“A minimally invasive, forward flow, fully unloading heart pump that is designed for surgery is game changing,” said Mark Anderson, M.D., chief of the Division of Cardiac Surgery and cardiothoracic surgeon at the Heart and Vascular Hospital at Hackensack University Medical Center and Hackensack Meridian Health. “This gives cardiac surgeons a new and potentially better option that can provide the benefits of heart recovery to some of our sickest patients.”

“The Impella 5.5 is designed to give severely ill patients the best chance for recovery of the heart," said Hermann Reichenspurner, M.D., Ph.D., professor and chief, Department of Cardiovascular Surgery, University Heart Center Hamburg. "A forward flow, minimally invasive heart pump that unloads the left ventricle and perfuses the end organs adequately is an ideal tool to help stabilize a patient after cardiac decompensation and give the heart time to rest and recover."

The FDA indication for use of Impella 5.5 with SmartAssist is as follows:

"The Impella 5.5 with SmartAssist System is a temporary ventricular support device intended for short-term (14 days) use and indicated for the treatment of ongoing cardiogenic shock that occurs immediately (< 48 hours) following acute myocardial infarction or open heart surgery or in the setting of cardiomyopathy, including peripartum cardiomyopathy, or myocarditis as a result of isolated left ventricular failure that is not responsive to optimal medical management and conventional treatment measures (including volume loading and use of pressors and inotropes, with or without IABP). The intent of Impella System Therapy is to reduce ventricular work and to provide the circulatory support necessary to allow heart recovery and early assessment of residual myocardial function."

Impella 5.5 with SmartAssist delivers peak flows of greater than 6 liters per minute. A motor housing that is thinner and 45 percent shorter than the Impella 5.0 improves ease of pump insertion through the vasculature.

The inclusion of SmartAssist enables intelligent decision making with weaning algorithms designed to increase survival with heart recovery. SmartAssist also integrates data informatics including left ventricular pressure (LVP), end-diastolic pressure (EDP) and cardiac power output (CPO). The SmartAssist fiberoptic pressure sensor allows for precise pump positioning, management and repositioning in the intensive care unit (ICU). Impella Connect enables clinicians to view the Impella control screen through a secure, HIPAA-compliant website to track and review cases at any time from any internet-connected device.

The Impella 5.5 with SmartAssist will be introduced in the United States through a controlled rollout at hospitals with established heart recovery protocols. Impella 5.5 with SmartAssist received CE marking approval in Europe in April 2018 and was introduced in Germany through a similar controlled rollout.

The supplement approval for the Impella 5.5 with SmartAssist stems from the FDA’s Impella PMA approvals indicating Impella devices as safe and effective for the treatment of cardiogenic shock. The approvals were based on analyses of Impella clinical results in 508 patients, which includes the FDA study RECOVER I, and the U.S. Impella registry, and of Impella literature reviews of 801 patients in 33 clinical studies. Additionally, more than 49,000 patients supported by Impella technology were reviewed in a safety analysis.

For more information: www.abiomed.com

Related Content

Impella SmartAssist Platform Launches at SCAI

FDA Approves Impella 5.0 and Impella LD Extended Duration of Use

PODCAST: The Hemodynamic Support Protocols at Henry Ford Hospital

Related Content

SpectraWave is developing a a new intravascular imaging system that combines two currently available modalities. This likely includes optical coherence tomography (OCT), left, which can define structures within the vessel and vessel wall.  Near infrared spectroscopy (NIRS), right, enables a spectral chemical analysis of the vessel walls to show areas of high lipid content, and specifically can identify lipid-core plaques that are associated with heart attack-causing plaque ruptures.

News | Cath Lab | February 16, 2021
February 16, 2021 – SpectraWave Inc.
Videos | Cath Lab | February 04, 2021
Cindy Grines, M.D., MSCAI, FACC, president
Among high-risk, chronic, coronary patients who undergo angioplasty, there were no additional benefits from ticagrelor compared to the current standard of care clopidogrel. #AHA #AHA20 #AHA2020
News | Cath Lab | November 16, 2020
November 16, 2020 — The use of the more potent antiplatelet medication ticagrelor (Brilinta) was not superior to clop
A large subgroup analysis of the VOYAGER PAD randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes was consistent regardless of whether a DCD was used. #TCT2020 #TCTconnect
Feature | Cath Lab | October 18, 2020
October 18, 2020 – A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benef
A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin capped fibrous atheroma (TCFA). #TCTconnect #TCT2020

A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin cap fibro-atheroma (TCFA).

News | Cath Lab | October 18, 2020
October 18, 2020 – Data from the...
The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions. #TCT2-0

The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions.

Feature | Cath Lab | October 16, 2020
October 15, 2020 — Shockwave Medical's Intravascular Lithotripsy (IVL) system to treat severely calcified coronary ar
Videos | Cath Lab | October 16, 2020
This is an example pf the Shockwave Medical Intravascular Lithotripsy (IVL) catheter system designed to break up heav
Videos | Cath Lab | July 15, 2020
Richard Botto, CVT, RCSA, chief cardiovascular technologist, division of cardiology, cardiac cath lab, offers an over